Filing Details

Longboard Pharmaceuticals, Inc.

(Name of Issuer)

Voting Common Stock, par value $0.0001 per share

(Title of Class of Securities)

54300N103

(Cusip Number)

December 31, 2023

(Date of Event which Requires Filing of this Statement)

☐	Rule 13d-1(b)
⌧	Rule 13d-1(c)
☐	Rule 13d-1(d)

13G

¹ Includes 645,490 Shares into which Non-Voting Shares are convertible within 60 days hereof.  Excludes 1,114,010 Shares into which Non-Voting Shares are not currently convertible due to the Beneficial Ownership Limitation (as defined in the Preliminary Note).

13G

13G

13G

13G

13G

13G

13G

13G

13G

¹ Includes 645,490 Shares into which Non-Voting Shares are convertible within 60 days hereof.  Excludes 1,114,010 Shares into which Non-Voting Shares are not currently convertible due to the Beneficial Ownership Limitation (as defined in the Preliminary Note).  See Preliminary Note.

13G

13G

13G

13G

¹ Includes 645,490 Shares into which Non-Voting Shares are convertible within 60 days hereof.  Excludes 1,114,010 Shares into which Non-Voting Shares are not currently convertible due to the Beneficial Ownership Limitation (as defined in the Preliminary Note).  See Preliminary Note.

13G

¹ Includes 645,490 Shares into which Non-Voting Shares are convertible within 60 days hereof.  Excludes 1,114,010 Shares into which Non-Voting Shares are not currently convertible due to the Beneficial Ownership Limitation (as defined in the Preliminary Note).

13G

¹ Includes 645,490 Shares into which Non-Voting Shares are convertible within 60 days hereof.  Excludes 1,114,010 Shares into which Non-Voting Shares are not currently convertible due to the Beneficial Ownership Limitation (as defined in the Preliminary Note).

13G

13G

¹ Includes 645,490 Shares into which Non-Voting Shares are convertible within 60 days hereof.  Excludes 1,114,010 Shares into which Non-Voting Shares are not currently convertible due to the Beneficial Ownership Limitation (as defined in the Preliminary Note).

13G

¹ Includes 645,490 Shares into which Non-Voting Shares are convertible within 60 days hereof.  Excludes 1,114,010 Shares into which Non-Voting Shares are not currently convertible due to the Beneficial Ownership Limitation (as defined in the Preliminary Note).

13G

¹ Includes 645,490 Shares into which Non-Voting Shares are convertible within 60 days hereof.  Excludes 1,114,010 Shares into which Non-Voting Shares are not currently convertible due to the Beneficial Ownership Limitation (as defined in the Preliminary Note).

13G

¹ Includes 645,490 Shares into which Non-Voting Shares are convertible within 60 days hereof.  Excludes 1,114,010 Shares into which Non-Voting Shares are not currently convertible due to the Beneficial Ownership Limitation (as defined in the Preliminary Note).

13G

¹ Includes 645,490 Shares into which Non-Voting Shares are convertible within 60 days hereof.  Excludes 1,114,010 Shares into which Non-Voting Shares are not currently convertible due to the Beneficial Ownership Limitation (as defined in the Preliminary Note).

13G

¹ Includes 645,490 Shares into which Non-Voting Shares are convertible within 60 days hereof.  Excludes 1,114,010 Shares into which Non-Voting Shares are not currently convertible due to the Beneficial Ownership Limitation (as defined in the Preliminary Note).

13G

¹ Includes 645,490 Shares into which Non-Voting Shares are convertible within 60 days hereof.  Excludes 1,114,010 Shares into which Non-Voting Shares are not currently convertible due to the Beneficial Ownership Limitation (as defined in the Preliminary Note).

13G

¹ Includes 645,490 Shares into which Non-Voting Shares are convertible within 60 days hereof.  Excludes 1,114,010 Shares into which Non-Voting Shares are not currently convertible due to the Beneficial Ownership Limitation (as defined in the Preliminary Note).

13G

¹ Includes 645,490 Shares into which Non-Voting Shares are convertible within 60 days hereof.  Excludes 1,114,010 Shares into which Non-Voting Shares are not currently convertible due to the Beneficial Ownership Limitation (as defined in the Preliminary Note).

13G

¹ Includes 645,490 Shares into which Non-Voting Shares are convertible within 60 days hereof.  Excludes 1,114,010 Shares into which Non-Voting Shares are not currently convertible due to the Beneficial Ownership Limitation (as defined in the Preliminary Note).

13G

¹ Includes 645,490 Shares into which Non-Voting Shares are convertible within 60 days hereof.  Excludes 1,114,010 Shares into which Non-Voting Shares are not currently convertible due to the Beneficial Ownership Limitation (as defined in the Preliminary Note).

13G

¹ Includes 645,490 Shares into which Non-Voting Shares are convertible within 60 days hereof.  Excludes 1,114,010 Shares into which Non-Voting Shares are not currently convertible due to the Beneficial Ownership Limitation (as defined in the Preliminary Note).

13G

¹ Includes 645,490 Shares into which Non-Voting Shares are convertible within 60 days hereof.  Excludes 1,114,010 Shares into which Non-Voting Shares are not currently convertible due to the Beneficial Ownership Limitation (as defined in the Preliminary Note).

This Amendment No. 3 to Schedule 13G amends and restates in its entirety the Schedule 13G initially filed on March 25, 2021 (together with all prior and current amendments thereto, this “Schedule 13G”).

Preliminary Note:

As of the date hereof, ZIIHH LLC and the Farallon Funds hold an aggregate of 1,560,500 Shares and 1,759,500 non-voting shares (the “Non-Voting Shares”), each of which is convertible, pursuant to the terms thereof, into one Share.

The terms of the Non-Voting Shares provide that Non-Voting Shares may not be converted if, after such conversion, the Reporting Persons would beneficially own, as determined in accordance with Section 13(d) of the Securities Exchange Act of 1934, as amended, more than 9.99% of the Shares then issued and outstanding (the “Beneficial Ownership Limitation”).  As of the date hereof, the Beneficial Ownership Limitation permits ZIIHH LLC to convert Non-Voting Shares into an aggregate of not more than 645,490 Shares.  In providing the beneficial ownership information set forth herein, the Reporting Persons have assumed that the aggregate remaining 1,114,010 Non-Voting Shares held by ZIIHH LLC are not exercisable due to the Beneficial Ownership Limitation.

Capitalized terms used in this Preliminary Note without definitions have the meanings ascribed to them below.

Item 1.

Issuer

Longboard Pharmaceuticals, Inc. (the “Company”)

4275 Executive Square, Suite 950

La Jolla, CA 92037

Item 2.

Identity and Background

Title of Class of Securities and CUSIP Number (Items 2(d) and (e))

This statement relates to shares of voting common stock, par value $0.0001 per share (the “Shares”), of the Company.  The CUSIP number of the Shares is 54300N103.

This statement is filed by the entities and persons listed below, all of whom together are referred to herein as the “Reporting Persons”.

(i)	Zone II Healthcare Holdings, LLC, a Delaware limited liability company (“ZIIHH LLC”), with respect to the Shares held by it and the Shares it has the right to acquire upon the conversion of Non-Voting Shares.

(ii)	Farallon Capital Partners, L.P., a California limited partnership (“FCP”), with respect to the Shares held by it;

(iii)

Farallon Capital Institutional Partners, L.P., a California limited partnership (“FCIP”), with respect to the Shares held by it;

(iv)	Farallon Capital Institutional Partners II, L.P., a California limited partnership (“FCIP II”), with respect to the Shares held by it;

(v)	Farallon Capital Institutional Partners III, L.P., a Delaware limited partnership (“FCIP III”), with respect to the Shares held by it;

(vi)	Four Crossings Institutional Partners V, L.P., a Delaware limited partnership (“FCIP V”), with respect to the Shares held by it;

(vii)

Farallon Capital Offshore Investors II, L.P., a Cayman Islands exempted limited partnership (“FCOI II”), with respect to the Shares held by it;

(viii)

Farallon Capital F5 Master I, L.P., a Cayman Islands exempted limited partnership (“F5MI”), with respect to the Shares held by it; and

(ix)	Farallon Capital (AM) Investors, L.P., a Delaware limited partnership (“FCAMI”), with respect to the Shares held by it.

FCP, FCIP, FCIP II, FCIP III, FCIP V, FCOI II, F5MI and FCAMI are together referred to herein as the “Farallon Funds.”

(x)	Farallon Capital Management, L.L.C., a Delaware limited liability company (the “Management Company”), which is the manager of ZIIHH LLC, with respect to the Shares held by ZIIHH LLC and the Shares ZIIHH LLC has the right to acquire upon the conversion of Non-Voting Shares.

(xi)

Farallon Partners, L.L.C., a Delaware limited liability company (the “Farallon General Partner”), which is (i) the general partner of each of FCP, FCIP, FCIP II, FCIP III, FCOI II and FCAMI, and (ii) the sole member of the FCIP V General Partner (as defined below), with respect to the Shares held by each of the Farallon Funds other than F5MI.

(xii)

Farallon Institutional (GP) V, L.L.C., a Delaware limited liability company (the “FCIP V General Partner”), which is the general partner of FCIP V, with respect to the Shares held by FCIP V.

The F5MI General Partner

(xiii)

Farallon F5 (GP), L.L.C., a Delaware limited liability company (the “F5MI General Partner”), which is the general partner of F5MI, with respect to the Shares held by F5MI.

The Farallon Individual Reporting Persons

(xiv)

The following persons, each of whom is a managing member or senior managing member, as the case may be, of the Management Company and the Farallon General Partner, and a manager or senior manager, as the case may be, of the FCIP V General Partner and the F5MI General Partner, with respect to the Shares held by ZIIHH LLC and the Farallon Funds and the Shares ZIIHH LLC has the right to acquire upon the conversion of Non-Voting Shares:  Joshua J. Dapice (“Dapice”); Philip D. Dreyfuss (“Dreyfuss”); Hannah E. Dunn (“Dunn”); Richard B. Fried (“Fried”); Varun N. Gehani (“Gehani”); Nicolas Giauque (“Giauque”); David T. Kim (“Kim”); Michael G. Linn (“Linn”); Rajiv A. Patel (“Patel”); Thomas G. Roberts, Jr. (“Roberts”); Edric C. Saito (“Saito”); William Seybold (“Seybold”); Daniel S. Short (“Short”); Andrew J. M. Spokes (“Spokes”); John R. Warren (“Warren”); and Mark C. Wehrly (“Wehrly”).

Dapice, Dreyfuss, Dunn, Fried, Gehani, Giauque, Kim, Linn, Patel, Roberts, Saito, Seybold, Short, Spokes, Warren and Wehrly are together referred to herein as the “Farallon Individual Reporting Persons.”

This Schedule 13G reports that effective June 30, 2023, Michael B. Fisch (“Fisch”) resigned as a member of the Management Company, a member of the Farallon General Partner, a manager of the FCIP V General Partner and a manager of the F5MI General Partner.  Accordingly, as of that date, Fisch no longer may be deemed a beneficial owner of any Shares or Non-Voting Shares held by ZIIHH LLC or any shares held by the Farallon Funds.  Unless the context otherwise requires, any reference herein to the “Farallon Individual Reporting Persons” shall not include Fisch.

The citizenship of each of ZIIHH LLC, the Farallon Funds, the Management Company, the Farallon General Partner, the FCIP V General Partner and the F5MI General Partner is set forth above. Each of Fisch and the Farallon Individual Reporting Persons, other than Giauque and Spokes, is a citizen of the United States.  Giauque is a citizen of France.  Spokes is a citizen of the United Kingdom.  The address of the principal business office of each of the Reporting Persons is c/o Farallon Capital Management, L.L.C., One Maritime Plaza, Suite 2100, San Francisco, California 94111.

Not applicable.

Item 4.

Ownership

The information required by Items 4(a) – (c) and set forth in Rows 5 through 11 of the cover page for each Reporting Person is incorporated herein by reference for each such Reporting Person.

The Shares and Non-Voting Shares reported hereby for ZIIHH LLC are held directly by ZIIHH LLC. The Shares reported hereby for the respective Farallon Funds are held directly by the respective Farallon Funds.  The Management Company, as the manager of ZIIHH LLC, may be deemed to be a beneficial owner of such Shares and Non-Voting Shares held by ZIIHH LLC.  The Farallon General Partner, as the general partner of each of FCP, FCIP, FCIP II, FCIP III, FCOI II and FCAMI, and as the sole member of the FCIP V General Partner, may be deemed to be a beneficial owner of such Shares held by the Farallon Funds other than F5MI.  The FCIP V General Partner, as the general partner of FCIP V, may be deemed to be a beneficial owner of such Shares held by FCIP V. The F5MI General Partner, as the general partner of F5MI, may be deemed to be a beneficial owner of such Shares held by F5MI.  Each of the Farallon Individual Reporting Persons, as a managing member or senior managing member, as the case may be, of the Management Company and the Farallon General Partner, and as a manager or senior manager, as the case may be, of the FCIP V General Partner and the F5MI General Partner, in each case with the power to exercise investment discretion, may be deemed to be a beneficial owner of such Shares and Non-Voting Shares held by ZIIHH LLC and the Farallon Funds.  Each of the Management Company, the Farallon General Partner, the FCIP V General Partner, the F5MI General Partner and the Farallon Individual Reporting Persons hereby disclaims any beneficial ownership of any such Shares and Non-Voting Shares.

Item 5.

Ownership of Five Percent or Less of a Class

If this statement is being filed to report the fact that as of the date hereof each of the Reporting Persons has ceased to be a beneficial owner of more than five percent of the class of securities, check the following:

Item 6.

Ownership of More than Five Percent on Behalf of Another Person

Not applicable.

 Not applicable.

The Reporting Persons are filing this Schedule 13G pursuant to Section 240.13d-1(c).  Consistent with Item 2 of the cover page for each Reporting Person above, the Reporting Persons neither disclaim nor affirm the existence of a group among them.

Item 9.

Notice of Dissolution of Group

Not applicable.

Item 10.

Certification

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a-11.

After reasonable inquiry and to the best of our knowledge and belief, the undersigned certify that the information set forth in this statement is true, complete and correct.

Dated:  January 30, 2024

The Powers of Attorney executed by each of Dapice, Dreyfuss, Fisch, Fried, Gehani, Giauque, Kim, Linn, Patel, Roberts, Saito, Seybold, Short, Spokes, Warren and Wehrly authorizing Dunn to sign and file this Schedule 13G on his behalf, which were filed as exhibits to the Schedule 13G filed with the Securities and Exchange Commission on January 31, 2023 by such Reporting Persons with respect to the Class A Ordinary Shares of ARYA Sciences Acquisition Corp IV, are hereby incorporated by reference.

EXHIBIT INDEX

EXHIBIT 1

to

SCHEDULE 13G

JOINT ACQUISITION STATEMENT

The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additional joint acquisition statements.  The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him, her or it contained therein, but shall not be responsible for the completeness and accuracy of the information concerning the other entities or persons, except to the extent that he, she or it knows or has reason to believe that such information is inaccurate.

Dated:  January 30, 2024